Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last ¥1,524 JPY
Change Today -30.50 / -1.96%
Volume 6.8M
4503 On Other Exchanges
As of 2:00 AM 10/8/15 All times are local (Market data is delayed by at least 15 minutes).

astellas pharma inc (4503) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/6/15 - ¥2,047
52 Week Low
10/17/14 - ¥1,482
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ASTELLAS PHARMA INC (4503)

Related News

No related news articles were found.

astellas pharma inc (4503) Related Businessweek News

View More BusinessWeek News

astellas pharma inc (4503) Details

Astellas Pharma Inc. manufactures, markets, and imports/exports pharmaceutical products worldwide. The company focuses on the therapeutic areas of urology, oncology, immunology, nephrology, neuroscience, muscle diseases, and ophthalmology. Its products include Prograf, an immunosuppressant to prevent rejection in organ transplants; Vesicare, a treatment for overactive bladder; Protopic, a treatment for atopic dermatitis in the topical immunomodulator class; Harnal, a blocking agent to treat the functional symptoms of benign prostatic hyperplasia; and Funguard, a candin antifungal agent. The company also offers Geninax, an oral new-type quinolone antibacterial agent; Celecox, a COX-2 inhibitor; Lipitor, a treatment for hypercholesterolemia; Micardis, a treatment for hypertension; Gaster, a treatment for peptic ulcers and gastritis; Myslee, a hypnotic; Cefzon, an oral cephalosporin; Seroquel, an antipsychotic agent; Dorner, a treatment for chronic arterial occlusion; Nasea, a 5-HT3 receptor antagonist; Regnite, a treatment for restless legs syndrome; and Kiklin, a treatment for hyperphatemia. In addition, it provides Lexiscan, a pharmacologic stress agent; Adenoscan, a pharmacologic stress agent; Tarceva, a treatment for non-small cell lung cancer; Vaprisol, a treatment for euvolemic hyponatremia; AmBisome, a systemic antifungal agent; Eligard, a treatment for advanced prostate cancer; Locoid, a topical corticosteroid; Zineryt, a treatment for acne; Locobase, a treatment for dry skin; and Dificlir, a novel treatment for CDI. The company has a collaboration with Chromocell Corporation to develop and commercialize treatments for neuropathic pain and other pain conditions. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.

17,113 Employees
Last Reported Date: 06/17/15
Founded in 1923

astellas pharma inc (4503) Top Compensated Officers

Chief Executive Officer, President and Repres...
Total Annual Compensation: ¥182.0M
Chief Administrative Officer, Chief Complianc...
Total Annual Compensation: ¥88.0M
Compensation as of Fiscal Year 2015.

astellas pharma inc (4503) Key Developments

Astellas Pharma and Chromocell Enter into Drug Development Collaboration for Neuropathic Pain

Astellas Pharma, Inc. and Chromocell Corporation have entered into a collaboration to develop and commercialise treatments for neuropathic pain and other pain conditions, the companies said in a statement. Under the agreement, Astellas receives global rights to commercialise pain treatment CC8464, as well as product candidates identified through Chromocell's Chromovert technology platform. Chromocell will receive an upfront payment of 15 million and is eligible to receive over 500 million in development and commercial milestones, as well as double-digit sales royalties from CC8464. In addition, Chromocell may suggest and initiate studies for additional indications, such as rare diseases and non-oral formulations of the drug candidate. Astellas would be eligible for inclusion into these additional developments, which would result in further payments for Chromocell and US co-promotion rights in some cases.

Astellas Pharma Inc. Announces Submission of Supplemental New Drug Application for ASP1585 Granule in Japan

Astellas Pharma Inc. announced that it submitted a supplemental new drug application for ASP1585 granule, an additional formulation of Kiklin Capsules 250 mg, for the indication of hyperphosphatemia in patients on dialysis with chronic kidney disease to the Ministry of Health, Labor and Welfare in Japan. Hyperphosphatemia occurs in patients whose renal function is reduced, since phosphorus is not sufficiently excreted into urine via the kidneys and consequently accumulates in the body. With continuous high blood phosphorus concentration, the risk of renal osteodystrophy characterized by a high tendency of bone pain and bone fracture is known to be increased. Additionally, high blood phosphorus concentration is associated with increased coronary artery calcification and subsequent cardiovascular events. Therefore, it is considered extremely important to maintain the serum phosphorus concentration at an appropriate level in CKD patients. Bixalomer is amine-functional polymers which decrease the serum phosphorus concentration by binding to phosphate in the gastrointestinal tract, thus inhibiting absorption of phosphate into the human body. Astellas expects to further contribute to hyperphosphatemia treatment by introducing ASP1585 granule which can further improve the compliance with its more convenient dosing option into Japanese market. In connection with the submission of this supplemental new drug application, there are no impact on Astellas' forecasts for fiscal year ending March 2016.

Astellas Pharma EMEA Announces Executive Changes

Astellas Pharma EMEA, the regional headquarters of Astellas Pharma Inc. for Europe, the Middle East and Africa, has appointed Eugene Van Rensburg to the position of Chief Financial Officer from his previous role as Senior Finance Director. Eugene succeeds Niek Stander, who will now head up the company's German operations as Managing Director of Astellas Pharma GmbH. As Chief Financial Officer, Eugene will oversee the Finance function across 40 countries in Europe, the Middle East and Africa, with responsibility for all financial planning and operations, as well as tax, treasury, procurement and information systems. Eugene has the expertise to enhance Astellas' operational efficiency and effectiveness as it undertakes strategic management of its expansion.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4503:JP ¥1,524.00 JPY -30.50

4503 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $135.52 USD -1.72
Boston Scientific Corp $16.57 USD -0.25
CSL Ltd A$90.95 AUD +0.78
Mylan NV $42.05 USD -0.18
Solvay SA €98.99 EUR +1.73
View Industry Companies

Industry Analysis


Industry Average

Valuation 4503 Industry Range
Price/Earnings 24.4x
Price/Sales 2.7x
Price/Book 2.6x
Price/Cash Flow 19.2x
TEV/Sales 2.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTELLAS PHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at